$Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study$

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

<p>Abstract</p> <p>Background</p> <p>The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However,...

Full description

Bibliographic Details
Main Authors:	Portales Fabienne, Bachet Jean-Baptiste, Lepère Céline, Boyer-Gestin Christine, Assenat Eric, Mitry Emmanuel, Samalin Emmanuelle, Lièvre Astrid, Vaillant Jean-Nicolas, Ychou Marc, Rougier Philippe
Format:	Article
Language:	English
Published:	BMC 2009-09-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/9/347

Similar Items

Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)
by: Pamela Baldin, et al.
Published: (2022-02-01)

Sustained Improvement in a Metastatic Colon Cancer Patient with FOLFIRI-Aflibercept after FOLFOX Failure
by: Shyam Aggarwal
Published: (2015-11-01)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
by: Elisa Giommoni, et al.
Published: (2021-05-01)

FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy
by: Nicolas Roussot, et al.
Published: (2023-11-01)

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
by: Francesca Foschini, et al.
Published: (2020-09-01)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
by: Erin D. Powell, et al.
Published: (2009-07-01)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
by: Abdosaleh Jafari, et al.
Published: (2023-05-01)

FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01)

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
by: Feng Wang, et al.
Published: (2019-05-01)

Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
by: Toshimitsu Tanaka, et al.
Published: (2022-08-01)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)

A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
by: Tomohiro Kanamaru, et al.
Published: (2015-03-01)

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID)
by: Hiroyuki Arai, et al.
Published: (2024-04-01)

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
by: Zeinab Hamidou, et al.
Published: (2016-01-01)

Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report
by: Minna Kim, et al.
Published: (2023-12-01)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
by: Takao Takahashi, et al.
Published: (2022-09-01)

Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX
by: Xi Zhang, et al.
Published: (2022-07-01)

Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment
by: Meiling Yang, et al.
Published: (2023-07-01)

Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study
by: M. Yu. Fedyanin, et al.
Published: (2022-03-01)

Retrospective exploratory analysis of <it>VEGF </it>polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
by: Manzoni Mariangela, et al.
Published: (2011-06-01)

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
by: Alessandro Ottaiano, et al.
Published: (2021-03-01)

Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer
by: Eun Mi Lee, et al.
Published: (2017-12-01)

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
by: Pectasides Dimitrios, et al.
Published: (2012-06-01)

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
by: Fotios Loupakis, et al.
Published: (2013-01-01)

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
by: Satoshi Takeuchi, et al.
Published: (2011-05-01)

Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors
by: Susan A. Kennedy, et al.
Published: (2020-10-01)

Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery
by: Andra Tilgase, et al.
Published: (2018-08-01)

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
by: Jiaqi Han MD, et al.
Published: (2020-02-01)

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
by: Lilian Schwarz, et al.
Published: (2018-07-01)

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
by: Yuta Ushida, et al.
Published: (2018-08-01)

Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
by: Girolamo Ranieri, et al.
Published: (2020-11-01)

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
by: Cals Laurent, et al.
Published: (2009-04-01)

Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study
by: Guohu Han, et al.
Published: (2023-12-01)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
by: Touroutoglou Nikolaos, et al.
Published: (2007-05-01)

Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
by: Chikako Funasaka, et al.
Published: (2019-08-01)

Corrigendum: Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
by: Girolamo Ranieri, et al.
Published: (2021-02-01)

Biochemical liver function test parameter levels in relation to treatment response in liver metastatic colorectal patients treated with FOLFOX4 with or without bevacizumab
by: Denić Kristina, et al.
Published: (2016-01-01)

Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy
by: Alexander Hendricks, et al.
Published: (2020-01-01)

Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial
by: Jacobus W A Burger, et al.
Published: (2024-01-01)

Severe proteinuria during the administration of bevacizumab plus mFOLFOX6 in a colorectal cancer patient after kidney transplantation: a case report
by: Ren Onodera, et al.
Published: (2020-09-01)